pituitary adenylate cyclaseactivating polypeptide 1–38 pacap  (Tocris)

Journal:

Article Title: Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone

doi:

Figure Lengend Snippet: Ligand-binding specificity of GHRH antagonist JV-1–42 binding. Competition for binding of radioligand 125I-JV-1–42 to membrane fractions of CAKI-1 human RCC was determined in the presence of increasing concentrations of JV-1–36 (■), JV-1–38 (□), MZ-5–156 (▿), hGHRH(1–44)NH2 (○), hGHRH(1–29)NH2 (●), and [His1,Nle27]hGHRH(1–32)NH2 (). VIP (♦) as well as glucagon, PACAP, JV-1–53, and PG 97–269 and other unrelated peptides, such as luteinizing hormone-releasing hormone, epidermal growth factor, [Tyr11]somatostatin-14, [Tyr4]bombesin, and IGF-I, did not displace the radioligand (data not shown). One hundred percent specific binding is defined as difference between binding in absence and in presence of 10−5 M JV-1–42. Each data point represents mean of at least two experiments, done in duplicate or triplicate.

Article Snippet: Agonistic analog [His 1 ,Nle 27 ]hGHRH(1–32)NH 2 , VIP, and pituitary adenylate cyclase-activating polypeptide (PACAP) were obtained from California Peptide Research (Napa, CA).

Techniques: Ligand Binding Assay, Binding Assay